Biofrontera completes Phase 1 study for Ameluz, sets FDA submission for 2026.

Biofrontera has completed the final patient visit in its Phase 1 pharmacokinetic study for Ameluz, a treatment for actinic keratoses on peripheral body areas. This marks a key milestone for FDA submission in summer 2026. The study, along with results from a recent Phase 3 clinical trial, will form the basis for FDA approval.